AbbVie (ABBV) Surged Following Strong Results and Increased Guidance

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index continued its rally in the third quarter, ending the year-to-date returns at 13.7%. During this period, growth and momentum were key contributors to the market's performance. A significant portion of the market is currently tied to the single catalyst of AI deployment, which means that any weaknesses in this concept could significantly threaten the market's future strength. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Carillon Eagle Growth & Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was -0.46%, and its shares gained 32.18% of their value over the last 52 weeks. On November 11, 2025, AbbVie Inc. (NYSE:ABBV) stock closed at $225.17 per share, with a market capitalization of $397.962 billion.

Carillon Eagle Growth & Income Fund stated the following regarding AbbVie Inc. (NYSE:ABBV) in its third quarter 2025 investor letter:

"AbbVie Inc. (NYSE:ABBV) issued a strong second-quarter financial update that included increased 2025 guidance. The company also announced a legal settlement with generic competitors that will result in three additional years of patent protection for one of its largest, and fastest- growing products."

AbbVie Inc. (NYSE:ABBV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 89 hedge fund portfolios held AbbVie Inc. (NYSE:ABBV) at the end of the second quarter, up from 86 in the previous quarter.  AbbVie Inc. (NYSE: ABBV) reported total net revenues of nearly $15.8 billion in Q3 2025, exceeding expectations by approximately $300 million. While we acknowledge the potential of AbbVie Inc. (NYSE:ABBV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered AbbVie Inc. (NYSE:ABBV) and shared the list of best DRIP stocks to own. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.